Spexis AG (SIX: SPEX) is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland, focused on developing macrocycle therapeutics for rare diseases and oncology. The company is led by Jeff Wager, M.D., Chairman & CEO. Spexis is advancing its ColiFin® program and plans upcoming Phase 3 studies, beginning with the COPILOT study expected to initiate in Q3 2023. To support that work, the company announced a capital commitment totaling USD $2.5m. The financing structure includes secured, interest-bearing debt with partial warrant coverage and subordinated debt that will convert into equity. Management intends to use the funds specifically for the Phase 3 ColiFin studies. Polyphor is a Basel-based biopharmaceutical company developing novel antibiotics, including a thanatin-derivative belonging to the OMPTA class. The program, discovered in collaboration with the University of Zurich, targets the LPS transport protein A (LptA) to disrupt the outer membrane of Gram-negative bacteria. It shows potent and specific antimicrobial activity against Enterobacteriaceae, including extremely drug-resistant strains such as Escherichia coli and Klebsiella pneumoniae. The program is in early stages of development and aims to treat life-threatening infections identified by WHO and the US CDC as urgent health threats. Polyphor has been awarded funding from CARB-X to support development, with an initial commitment and additional milestone-contingent support available. If successful and approved, the therapy could change treatment options for multidrug-resistant Gram-negative infections. Polyphor is a clinical-stage specialty pharma based in Allschwil, Switzerland, focused on developing macrocycle drugs to address antibiotic resistance and severe respiratory diseases. Its lead antibiotic Murepavadin (POL7080) is in Phase II and entering a pivotal registration program against Pseudomonas aeruginosa. The company is also advancing POL6014 (Phase Ib), an inhaled neutrophil elastase inhibitor for cystic fibrosis and severe lung diseases, and balixafortide (POL6326, Phase Ib), a CXCR4 antagonist for oncology combination therapy. Polyphor plans to use new funding to finance the pivotal registration program for Murepavadin, a proof-of-concept program for POL6014, and completion of preclinical work to advance additional antibiotic candidates into the clinic. Giacomo Di Nepi leads the company as CEO.

Total raised

$45M

Funding rounds

4

Latest round

Debt Financing

Latest activity

Aug 2023